Claims for Patent: 8,409,574

Summary for Patent: 8,409,574

Title:	Taxane analogs for the treatment of brain cancer
Abstract:	Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
Inventor(s):	McChesney; James D. (Etta, MS), Tapolsky; Gilles (Boulder, CO), Emerson; David E. (Longmont, CO), Marshall; John (Washington, DC), Ahmed; Tauseef (Briarcliff Manor, NY), Cohn; Allen (Englewood, CO), Kurman; Michael (Upper Saddle River, NJ), Modiano; Manuel (Tucson, AZ)
Assignee:
Application Number:	12/859,990
Patent Claims:	1. A method for the treatment of brain cancer in a mammal, the method comprising the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein, wherein said compound has the structure of formula (1): ##STR00025## 2. The method of claim 1, wherein the administration is by an oral administration. 3. The method of claim 1, wherein the compound has the structure of formula R-(1) ##STR00026## 4. The method of claim 1 wherein the compound is of the formula S-(1): ##STR00027## 5. The method of claim 1 wherein a further anticancer agent is also administered in combination with the compound. 6. The method for the treatment of brain cancer according to claim 5, wherein the further anticancer agent is selected from the group consisting of aromatase inhibitors, antiestrogen, anti-androgen, gonadorelin agonists, topoisomerase 1 inhibitors, topoisomerase 2 inhibitors, microtubule active agents, alkylating agents, anthracyclines, corticosteroids, IMiDs, protease inhibitors, IGF-1 inhibitors, CD40 antibodies, Smac mimetics, FGF3 modulators, mTOR inhibitors, HDAC inhibitors, IKK inhibitors, P38MAPK inhibitors, HSP90 inhibitors, akt inhibitors, antineoplastic agents, antimetabolites, platin containing compounds, lipid- or protein kinase-targeting agents, protein- or lipid phosphatase-targeting agents, anti-angiogentic agents, agents that induce cell differentiation, bradykinin 1 receptor antagonists, angiotensin II antagonists, cyclooxygenase inhibitors, heparanase inhibitors, lymphokine inhibitors, cytokine inhibitors, bisphosphanates, rapamycin derivatives, anti-apoptotic pathway inhibitors, apoptotic pathway agonists, PPAR agonists, inhibitors of Ras isoforms, telomerase inhibitors, protease inhibitors, metalloproteinase inhibitors, and aminopeptidase inhibitors. 7. The method for the treatment of brain cancer according to claim 5, wherein the further anticancer agent is selected from the group consisting of temozolomide, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, oxaliplatin, leucovirin, oxaliplatin, pentostatine, vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mithramycin, deoxycoformycin, mitomycin-c, 1-asparaginase, teniposide, 7a-ethinylestradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, dromostanolone propionate, testolactone, megestrolacetate, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesteroneacetate, leuprolide, flutamide, toremifene, goserelin, cisplatin, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, navelbene, anastrazole, letrazole, capecitabine, reloxafine, droloxafine, hexamethylmelamine, doxorubicin, cyclophosphamide, gemcitabine, interferons, pegylated interferons, erbitux and mixtures thereof. 8. The method for the treatment of brain cancer according to claim 5, wherein further anticancer agent is selected from the group consisting of temozolomide, cisplatin, 5- fluorouracil, taxotere, gemcitabine, and bevacizumab. 9. The method for the treatment of brain cancer according to claim 1, wherein the brain cancer is selected from the group consisting of astrocytoma, craniopharyngioma, glioma, ependymoma, neuroglioma, oligodendroglioma, neuroblastoma, glioblastoma multiforme, meningioma, medulloblastoma and other primitive neuroectoderma. 10. The method for the treatment of brain cancer according to claim 1, wherein the brain cancer is a metastasis of a primary tumor or metastases external to the brain. 11. The method for the treatment of brain cancer according to claim 10, wherein the brain cancer, and the primary tumor or metastases external to the brain are treated simultaneously. 12. The method for the treatment of brain cancer according to claim 10, wherein the primary tumor or metastases external to the brain are selected from the group consisting of breast cancer, small cell lung cancer, lymphoma and germ cell cancers.

Details for Patent 8,409,574

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2027-02-28
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2027-02-28
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2027-02-28
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2027-02-28